New Horizons Project

About the Project

HIV has shifted in its definition from a fatal disease to a chronic illness thanks to effective treatment regimens. Long-term treatment, however effective, can become less effective or ineffective over a lifetime, especially when treatment interruptions take place. With more and more children and adolescents diagnosed and enrolled on lifelong ART, demand for second- and third-line treatment is expected to increase in coming years. Prevention and management of treatment failure in children and adolescents living with HIV must be prioritized to achieve and maintain viral suppression and prevent drug resistance in a population suffering from increasing HIV-related morbidity and mortality.

In response to a gap in the availability of second- and third-line treatment options for HIV-infected children, adolescents, and young people, Johnson & Johnson Global Public Health, EGPAF, and the Partnership for Supply Chain Management launched the New Horizons Advancing Pediatric HIV Care Collaborative in 2014. Since its establishment, several additional partners have joined the initiative, including Right to Care, the Relevance Network, and the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) of the International AIDS Society (IAS). Its mission is to advance a holistic, integrated approach to lifelong, effective HIV care and treatment for children, adolescents, and young people, with a particular focus on those in need of second- and third-line medications.

Key objectives of the collaborative include: 1) addressing the gap between pediatric and adult HIV and AIDS treatment; 2) targeting challenges sustainable antiretroviral therapy (ART) service delivery for children, adolescents, and young people; and 3) building awareness of and confronting challenges faced by adolescents and young people concerning disclosure, adherence, psychosocial support, retention, and transition to adult care.

The collaborative supports several platforms for reaching its objectives of addressing an immediate humanitarian need for advanced ART for children, adolescents, young people and supporting health systems strengthening national HIV and AIDS programs. A darunavir (DRV)/etravirine (ETR) donation program, was launched in 2014 by this collaborative to increase access to third-line HIV medication for children, adolescents, young people experiencing treatment failure on second-line. Countries participating in New Horizons include Cameroon, Eswatini Ethiopia, Kenya, Lesotho, Nigeria, Rwanda, South Africa, Uganda, Zambia, Zimbabwe; South Africa is the only country among the ten that is not receiving product donations.

New Horizons Collaborative

EGPAF supports the New Horizons expression of interest (EOI) application process and convenes an expert review committee to ascertain readiness of countries willing to participate in this donation program and capacity building needs. EOI applications may be submitted by Ministries of Health or a designee from countries in sub-Saharan Africa and countries considered to be least developed by the United Nations. New Horizons will accept applications on a quarterly basis through mid 2019. Additional information and application materials can be found here.



Related Content